These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

684 related articles for article (PubMed ID: 22942876)

  • 21. Group II Metabotropic Glutamate Receptors: Role in Pain Mechanisms and Pain Modulation.
    Mazzitelli M; Palazzo E; Maione S; Neugebauer V
    Front Mol Neurosci; 2018; 11():383. PubMed ID: 30356691
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Recent Advances in the Modulation of Pain by the Metabotropic Glutamate Receptors.
    Mazzitelli M; Presto P; Antenucci N; Meltan S; Neugebauer V
    Cells; 2022 Aug; 11(16):. PubMed ID: 36010684
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Metabotropic glutamate receptors as drug targets.
    Récasens M; Guiramand J; Aimar R; Abdulkarim A; Barbanel G
    Curr Drug Targets; 2007 May; 8(5):651-81. PubMed ID: 17504108
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Allosteric modulators for mGlu receptors.
    Gasparini F; Spooren W
    Curr Neuropharmacol; 2007 Sep; 5(3):187-94. PubMed ID: 19305801
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Targeting mGluR2/3 for treatment of neurodegenerative and neuropsychiatric diseases.
    Li SH; Abd-Elrahman KS; Ferguson SSG
    Pharmacol Ther; 2022 Nov; 239():108275. PubMed ID: 36038019
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The glutamatergic system as a target for neuropathic pain relief.
    Osikowicz M; Mika J; Przewlocka B
    Exp Physiol; 2013 Feb; 98(2):372-84. PubMed ID: 23002244
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Modulation of excitatory neurotransmission by neuronal/glial signalling molecules: interplay between purinergic and glutamatergic systems.
    Köles L; Kató E; Hanuska A; Zádori ZS; Al-Khrasani M; Zelles T; Rubini P; Illes P
    Purinergic Signal; 2016 Mar; 12(1):1-24. PubMed ID: 26542977
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Glutamatergic mechanisms in different disease states: overview and therapeutical implications -- an introduction.
    Tzschentke TM
    Amino Acids; 2002; 23(1-3):147-52. PubMed ID: 12373529
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Metabotropic glutamate receptors and interacting proteins: evolving drug targets.
    Enz R
    Curr Drug Targets; 2012 Jan; 13(1):145-56. PubMed ID: 21777188
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Targeting mGluR group III for the treatment of neurodegenerative diseases.
    Rabeh N; Hajjar B; Maraka JO; Sammanasunathan AF; Khan M; Alkhaaldi SMI; Mansour S; Almheiri RT; Hamdan H; Abd-Elrahman KS
    Biomed Pharmacother; 2023 Dec; 168():115733. PubMed ID: 37862967
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Group I Metabotropic Glutamate Receptors (mGluRs): Ins and Outs.
    Mahato PK; Ramsakha N; Ojha P; Gulia R; Sharma R; Bhattacharyya S
    Adv Exp Med Biol; 2018; 1112():163-175. PubMed ID: 30637697
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Metabotropic and ionotropic glutamate receptors as potential targets for the treatment of alcohol use disorder.
    Goodwani S; Saternos H; Alasmari F; Sari Y
    Neurosci Biobehav Rev; 2017 Jun; 77():14-31. PubMed ID: 28242339
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Clinical investigations of compounds targeting metabotropic glutamate receptors.
    Witkin JM; Pandey KP; Smith JL
    Pharmacol Biochem Behav; 2022 Sep; 219():173446. PubMed ID: 35987339
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The chemical biology of clinically tolerated NMDA receptor antagonists.
    Chen HS; Lipton SA
    J Neurochem; 2006 Jun; 97(6):1611-26. PubMed ID: 16805772
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Parkinson's disease, epilepsy, and amyotrophic lateral sclerosis-emerging role of AMPA and kainate subtypes of ionotropic glutamate receptors.
    Vukolova MN; Yen LY; Khmyz MI; Sobolevsky AI; Yelshanskaya MV
    Front Cell Dev Biol; 2023; 11():1252953. PubMed ID: 38033869
    [TBL] [Abstract][Full Text] [Related]  

  • 36. New therapeutic frontiers for metabotropic glutamate receptors.
    Niswender CM; Jones CK; Conn PJ
    Curr Top Med Chem; 2005; 5(9):847-57. PubMed ID: 16178730
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Recent developments of the PET imaging agents for metabotropic glutamate receptor subtype 5.
    Yu M
    Curr Top Med Chem; 2007; 7(18):1800-5. PubMed ID: 17979788
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Role of Metabotropic Glutamate Receptors in Neurological Disorders.
    Crupi R; Impellizzeri D; Cuzzocrea S
    Front Mol Neurosci; 2019; 12():20. PubMed ID: 30800054
    [TBL] [Abstract][Full Text] [Related]  

  • 39.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 40.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 35.